Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90%
- Resource Type
- Article
- Source
- In
JTO Clinical and Research Reports December 2023 4(12) - Subject
- Language
- ISSN
- 2666-3643